WallStreetZenWallStreetZen

NASDAQ: ACIU
Ac Immune Sa Stock Forecast, Predictions & Price Target

Analyst price target for ACIU

Based on 1 analyst offering 12 month price targets for Ac Immune Sa.
Min Forecast
$16.00+598.69%
Avg Forecast
$16.00+598.69%
Max Forecast
$16.00+598.69%

Should I buy or sell ACIU stock?

Based on 1 analyst offering ratings for Ac Immune Sa.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ACIU stock forecasts and price targets.

ACIU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-15

1 of 1

Forecast return on equity

Is ACIU forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is ACIU forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ACIU revenue forecast

What is ACIU's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$14.2M-19.69%
Avg 2 year Forecast
$68.9M+291.25%
Avg 3 year Forecast
$112.4M+538.13%
ACIU's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ACIU revenue growth forecast

How is ACIU forecast to perform vs Biotechnology companies and vs the US market?
Company
89.72%
Industry
37.04%
Market
9.92%
ACIU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ACIU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ACIU vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACIU$2.29$16.00+598.69%Buy
QSI$1.61$4.00+148.45%Buy
CDT$3.10N/AN/A
FHTX$5.23$13.00+148.57%Buy
ALDX$3.94$10.00+153.81%Buy

Ac Immune Sa Stock Forecast FAQ

Is Ac Immune Sa Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ACIU) stock is to Buy ACIU stock.

Out of 1 analyst, 0 (0%) are recommending ACIU as a Strong Buy, 1 (100%) are recommending ACIU as a Buy, 0 (0%) are recommending ACIU as a Hold, 0 (0%) are recommending ACIU as a Sell, and 0 (0%) are recommending ACIU as a Strong Sell.

If you're new to stock investing, here's how to buy Ac Immune Sa stock.

What is ACIU's revenue growth forecast for 2024-2026?

(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 89.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Ac Immune Sa's revenue in 2024 is $16,819,318.On average, 2 Wall Street analysts forecast ACIU's revenue for 2024 to be $1,403,649,280, with the lowest ACIU revenue forecast at $1,125,895,359, and the highest ACIU revenue forecast at $1,681,403,202. On average, 3 Wall Street analysts forecast ACIU's revenue for 2025 to be $6,838,698,331, with the lowest ACIU revenue forecast at $2,678,341,383, and the highest ACIU revenue forecast at $14,955,064,700.

In 2026, ACIU is forecast to generate $11,153,803,893 in revenue, with the lowest revenue forecast at $3,197,146,029 and the highest revenue forecast at $19,110,461,757.

What is ACIU's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ACIU) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ACIU's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ACIU price target, the average ACIU price target is $16.00, with the highest ACIU stock price forecast at $16.00 and the lowest ACIU stock price forecast at $16.00.

The Wall Street analyst predicted that Ac Immune Sa's share price could reach $16.00 by Mar 15, 2025. The average Ac Immune Sa stock price prediction forecasts a potential upside of 598.69% from the current ACIU share price of $2.29.

What is ACIU's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ACIU) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.